Syndax Pharmaceuticals, Inc. Increase (Decrease) in Restricted Cash
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Restricted Cash of -$45.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-08
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $6.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for the quarter ending 2017-09-30 was -$1.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was -$1.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was -$49.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for fiscal 2017 was -$45.00K, a 146.39% decline from fiscal 2016.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for fiscal 2016 was $97.00K, a 17.80% decline from fiscal 2015.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for fiscal 2015 was $118.00K, a 11700.00% increase from fiscal 2014.
- Syndax Pharmaceuticals, Inc. increase (decrease) in restricted cash for fiscal 2014 was $1.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $5.00K derived: sum of 2 quarters · filed 2018-03-08 | $4.00K derived: sum of 3 quarters · filed 2018-03-08 | -$45.00K 10-K · filed 2018-03-08 |
| 2017-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$2.00K derived: sum of 2 quarters · filed 2017-11-08 | -$51.00K 10-Q · filed 2017-11-08 | -$54.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$50.00K 10-Q · filed 2017-08-10 | -$53.00K derived: sum of 3 quarters · filed 2018-03-08 | |
| 2017-03-31 | -$49.00K 10-Q · filed 2017-05-09 | -$52.00K derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2016-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $97.00K 10-K · filed 2018-03-08 | ||
| 2016-09-30 | $100.00K 10-Q · filed 2017-11-08 | |||
| 2016-03-31 | -$2.00K 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $118.00K 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $1.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |